HUP0202253A3 - Selective iglur5 receptor antagonists for the treatment of migraine - Google Patents

Selective iglur5 receptor antagonists for the treatment of migraine

Info

Publication number
HUP0202253A3
HUP0202253A3 HU0202253A HUP0202253A HUP0202253A3 HU P0202253 A3 HUP0202253 A3 HU P0202253A3 HU 0202253 A HU0202253 A HU 0202253A HU P0202253 A HUP0202253 A HU P0202253A HU P0202253 A3 HUP0202253 A3 HU P0202253A3
Authority
HU
Hungary
Prior art keywords
migraine
treatment
receptor antagonists
iglur5 receptor
selective iglur5
Prior art date
Application number
HU0202253A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP0202253A2 publication Critical patent/HUP0202253A2/hu
Publication of HUP0202253A3 publication Critical patent/HUP0202253A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0202253A 1999-07-06 2000-06-27 Selective iglur5 receptor antagonists for the treatment of migraine HUP0202253A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27

Publications (2)

Publication Number Publication Date
HUP0202253A2 HUP0202253A2 (hu) 2002-11-28
HUP0202253A3 true HUP0202253A3 (en) 2003-12-29

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202253A HUP0202253A3 (en) 1999-07-06 2000-06-27 Selective iglur5 receptor antagonists for the treatment of migraine

Country Status (28)

Country Link
US (4) US6566370B1 (enExample)
EP (1) EP1200073B1 (enExample)
JP (1) JP4619595B2 (enExample)
KR (1) KR20020024300A (enExample)
CN (1) CN1230174C (enExample)
AR (1) AR029373A1 (enExample)
AU (1) AU773304B2 (enExample)
BR (1) BR0012175A (enExample)
CA (1) CA2378613C (enExample)
CZ (1) CZ20014488A3 (enExample)
DE (1) DE60032905T2 (enExample)
DK (1) DK1200073T3 (enExample)
DZ (1) DZ3209A1 (enExample)
EA (1) EA004290B1 (enExample)
ES (1) ES2278619T3 (enExample)
HK (1) HK1047036A1 (enExample)
HR (1) HRP20020013A2 (enExample)
HU (1) HUP0202253A3 (enExample)
IL (1) IL146697A0 (enExample)
MX (1) MXPA01012726A (enExample)
MY (1) MY133503A (enExample)
NO (1) NO20016246L (enExample)
NZ (1) NZ515616A (enExample)
PE (1) PE20010299A1 (enExample)
PT (1) PT1200073E (enExample)
SK (1) SK112002A3 (enExample)
TR (1) TR200200066T2 (enExample)
WO (1) WO2001001972A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2574801A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002053139A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
CZ20031856A3 (cs) * 2001-01-05 2003-09-17 Eli Lilly And Company Antagonisté receptorů excitačních aminokyselin
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6855725B2 (en) * 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002053555A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
PT1511741E (pt) 2002-04-26 2013-02-05 Lilly Co Eli Derivados éster de um ácido deca-hidroisoquinolino-3- carboxílico como analgésicos
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
KR20090083479A (ko) 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
WO2019171258A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
TW202245744A (zh) 2021-02-09 2022-12-01 加拿大商再諾製藥公司 治療失樂症之方法及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
TR199902449T2 (xx) * 1997-04-07 2000-07-21 Eli Lilly And Company Farmakolojik etkin maddeler.
DE60002733T2 (de) 1999-07-06 2004-03-18 Eli Lilly And Co., Indianapolis Diester prodrugs von decahydroischinoline-3-carbonsäure

Also Published As

Publication number Publication date
DE60032905D1 (de) 2007-02-22
HK1047036A1 (zh) 2003-02-07
DZ3209A1 (fr) 2001-01-11
US7157582B2 (en) 2007-01-02
WO2001001972A3 (en) 2001-12-06
TR200200066T2 (tr) 2002-04-22
US6855823B2 (en) 2005-02-15
CA2378613C (en) 2007-10-02
WO2001001972A2 (en) 2001-01-11
HUP0202253A2 (hu) 2002-11-28
EA004290B1 (ru) 2004-02-26
MXPA01012726A (es) 2002-07-02
US6566370B1 (en) 2003-05-20
JP2003503449A (ja) 2003-01-28
SK112002A3 (en) 2003-05-02
NO20016246D0 (no) 2001-12-19
US6759418B2 (en) 2004-07-06
AU5873200A (en) 2001-01-22
EP1200073A2 (en) 2002-05-02
CZ20014488A3 (cs) 2003-01-15
AU773304B2 (en) 2004-05-20
US20050159445A1 (en) 2005-07-21
EP1200073B1 (en) 2007-01-10
US20030199546A1 (en) 2003-10-23
ES2278619T3 (es) 2007-08-16
US20040192722A1 (en) 2004-09-30
CN1359289A (zh) 2002-07-17
NZ515616A (en) 2004-05-28
BR0012175A (pt) 2002-03-05
PE20010299A1 (es) 2001-03-07
PT1200073E (pt) 2007-03-30
EA200200132A1 (ru) 2002-06-27
HRP20020013A2 (en) 2003-08-31
IL146697A0 (en) 2002-07-25
NO20016246L (no) 2002-03-04
CA2378613A1 (en) 2001-01-11
CN1230174C (zh) 2005-12-07
MY133503A (en) 2007-11-30
JP4619595B2 (ja) 2011-01-26
AR029373A1 (es) 2003-06-25
KR20020024300A (ko) 2002-03-29
DE60032905T2 (de) 2007-10-18
DK1200073T3 (da) 2007-05-07

Similar Documents

Publication Publication Date Title
IL146697A0 (en) SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
HUP0201184A2 (en) Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction
NO20032360L (no) EP4 reseptor selektive agonister for behandling av osteoporose
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
PL352056A1 (en) Antagonists of bradykinin receptor
AU2003267088A8 (en) Chemokine receptor antagonists as therapeutic agents
PL350536A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor
PL370842A1 (en) Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction
GC0000203A (en) Vitronectin receptor antagonists
EP1180025A4 (en) IL-8 RECEPTOR ANTAGONISTS
HUP0001891A2 (en) Medicament for the treatment of migraine
IL142362A0 (en) Ureidopiperidine derivatives as selective human nk3 receptor antagonists
EP1208101A4 (en) VITRONECTIN RECEPTOR ANTAGONISTS USEFUL FOR THE TREATMENT OF VASCULAR ACCIDENTS
PL371270A1 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
AU2002219192A1 (en) Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
IL149266A0 (en) Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia
PL352222A1 (en) Antagonists of the il-8 receptor
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
IL123740A0 (en) NK-1 receptor antagonists for the treatment of delayed emesis
GB9904441D0 (en) Homology models of the glucocorticoid receptor
GB9909151D0 (en) Homology models of the glucocorticoid receptor

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees